MindMed

Biotechnology ResearchNew York, United States51-200 Employees

MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

Social Media Guidelines: https://d1io3yog0oux5.cloudfront.net/_0e89882e36c19f988d288d9e6cd98de2/mindmed/db/2275/21511/file/MNMD+Community+Guidelines+FINAL+030325.pdf

Sign up for free to view info

Email Format Employee directory